Aliquot and freeze in liquid nitrogen; store aliquots frozen at -80°C up to 1 year. Thaw aliquots at 37°C. Thawed aliquots may be stored at 4°C up to 3 months.

Avoid repeated freeze / thaw cycles.

Stability:
The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).

Mab βA4(42)-8G7 specifically interacts with the C-Terminus of β-Amyloid (1 - 42) and does not crossreact with β-Amyloid (1 - 40).

Purification: The antibody was purified from serum-free cell culture supernatant by subsequent thiophilic adsorption and size exclusion chromatography.

Formulation: liquid; 0.5 mg/ml in PBS/0.09% Na-Azide/PEG and Sucrose

Reconstitution: Aliquote and freeze in liquid nitrogen; store aliquots frozen at -80°C up to 1 year. Thaw aliquots at 37°C. Thawed aliquots may be stored at 4°C up to 3 months.

Avoid repeated freeze / thaw cycles.

Positive Control: none

Immunoblotting: Please use unlabelled or biotinylated antibody for this application. See related products.

Immunoprecipitation: ND

Immunocytochemistry: use at 1 - 10 μg/ml

ELISA: ND

All products are supplied for research and investigational use only. Not for use in humans or laboratory animals.

Mouse Monoclonal Antibody to

**Amyloid βA4 (1-42), C-Terminus**

**clone 8G7**

**FITC-labelled**

**Order No.:** 0061-100FITC/bA4(42)-8G7

**Size (μg):** 100

**Lot No.:** 0061S

**Isotype:** IgG1

**Species Reactivity:** human

**Applications:** ICC

**Mol. Weight:** none

**Ref.Cell Line:** C-Terminus of Amyloid βA4 (1-42), does not crossreact with βA4 (1-40)

**Immunogen:** C-terminal peptide conjugated to KLH

**Background and Specificity:**

The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).

Mab βA4(42)-8G7 specifically interacts with the C-Terminus of β-Amyloid (1 - 42) and does not crossreact with β-Amyloid (1 - 40).

**Related Products**

- mab to βA4, N-Terminus #0064-100bA4N-19H5
- mab to βA4, N-Terminus #0084-100bA4N-19H11
- mab to βA4, N-Terminus #0195-100bA4N-7F4
- mab to βA4, N-Terminus #0196-100bA4N-7F9
- mab to βA4, N-Terminus #0197-100bA4N-11H3
- mab to βA4 (1-40), C-Terminus #0060-100bA4(40)-5C3
- mab to βA4 (1-40/42), C-Terminus #0062-100bA4(40/42)-9F1
- mab to βA4 (1-42), C-Terminus #0061-100bA4(42)-8G7
- mab to βA4 (1-43), C-Terminus #0095-100bA4(43)-6G12

**Order No.:** 0061S

**Lot No.:** 03/020307F

**Immunogen:** C-terminal peptide conjugated to KLH

**Epitope:** ICC

**Applications:** none

**Mol. Weight:** none

**Ref.Cell Line:** C-Terminus of Amyloid βA4 (1-42), does not crossreact with βA4 (1-40)

**Immunogen:** C-terminal peptide conjugated to KLH

**Background and Specificity:**

The beta-amyloid peptide (beta A4), proteolytically released from the amyloid precursor protein (APP), is the principal component of senile plaques in Alzheimer's disease. Cleavage of APP by alpha-secretase or alternatively by beta-secretase leads to generation and extracellular release of soluble APP peptides, S-APP-alpha and S-APP-beta, respectively, and the retention of corresponding membrane-anchored C-terminal fragments, C83 and C99. Subsequent processing of C83 by gamma-secretase yields P3 peptides. This is the major secretory pathway and is nonamyloidogenic. Alternatively, presenilin/nicastrin-mediated gamma-secretase processing of C99 releases the amyloid beta proteins, amyloid-beta 40 (Abeta40) and amyloid-beta 42 (Abeta42), major components of amyloid plaques, and the cytotoxic C-terminal fragments, gamma-CTF(50), gamma-CTF(57) and gamma-CTF(59).

Mab βA4(42)-8G7 specifically interacts with the C-Terminus of β-Amyloid (1 - 42) and does not crossreact with β-Amyloid (1 - 40).

**Purification:** The antibody was purified from serum-free cell culture supernatant by subsequent thiophilic adsorption and size exclusion chromatography.

**Formulation:** liquid; 0.5 mg/ml in PBS/0.09% Na-Azide/PEG and Sucrose

**Reconstitution:** Aliquote and freeze in liquid nitrogen; store aliquots frozen at -80°C up to 1 year. Thaw aliquots at 37°C. Thawed aliquots may be stored at 4°C up to 3 months.

**Stability:** Avoid repeated freeze / thaw cycles.

**Positive Control:** none

**Immunoblotting:** Please use unlabelled or biotinylated antibody for this application. See related products.